Clinical Trials Logo

Clinical Trial Details — Status: Completed

Administrative data

NCT number NCT02785978
Other study ID # Pre-QuantiPark
Secondary ID
Status Completed
Phase N/A
First received May 11, 2016
Last updated October 9, 2017
Start date June 2016
Est. completion date July 2017

Study information

Verified date October 2017
Source Institut de Myologie, France
Contact n/a
Is FDA regulated No
Health authority
Study type Interventional

Clinical Trial Summary

Pre-QuantiPark is a pilot study to evaluate the reliability and responsiveness of ActiMyo measured activity in PD patients. The purpose of the study is to provide validation of the ActiMyo, an innovative home-recording device enabling use in clinical trials and as an innovative tool for PD patient care.


Recruitment information / eligibility

Status Completed
Enrollment 30
Est. completion date July 2017
Est. primary completion date June 2017
Accepts healthy volunteers Accepts Healthy Volunteers
Gender All
Age group 18 Years and older
Eligibility Patients:

Inclusion criteria

- Clinical diagnosis of idiopathic PD (UKPDSBB criteria)

- On stable parkinsonian medication regimen including levodopa for at least 4 weeks

- Male of female aged =18 years old

- Experiencing motor fluctuations and dyskinesia

- MoCA (Montreal Cognitive Assessment) = 26

- Willing to adhere and comply to the protocol requirements as evi-dence by written informed consent

- Capable and willing to accurately using Actimyo

- Capable and willing to complete diaries

- Unlimited broadband internet access at home

- Agrees to be filmed

- Affiliated to or a beneficiary of a social security scheme

- PD patients subgroup #1 only: levodopa acute test scheduled as part of usual care

Exclusion Criteria

- Undergone surgery for the treatment of PD

- Apomorphine or Levodopa Pump in place

- Deep brain stimulation or transcranial magnetic stimulation

- Drug-induced parkinsonism

- Vascular parkinsonism

- Parkinson plus syndromes (such as multiple system atrophy, pro-gressive supranuclear palsy, and corticobasal degeneration)

- Other neurodegenerative disorders

- Any other significant medical or psychiatric illness that could inter-fere with study evaluation

- For women: pregnancy or current breastfeeding

- Under legal protection

Healthy subjects:

Inclusion criteria

- Male of female matched by age with PD patients ; aged = 18

- Willing to adhere and comply to the protocol requirements as evi-dence by written informed consent

- Capable and willing to accurately using Actimyo

- Capable and willing to complete diaries

- MoCA (Montreal Cognitive Assessment) = 26

- Unlimited broadband internet access at home

- Agrees to be filmed

- Affiliated to or a beneficiary of a social security scheme

Exclusion Criteria

- Any significant medical or psychiatric illness that could interfere with study evaluation

- For women: pregnancy or current breastfeeding

- Under legal protection

- Close or near relation of investigators, Institute of Myology employ-ees, or AFM-Telethon members.

Study Design


Related Conditions & MeSH terms


Intervention

Drug:
Levodopa acute challenge
Inclusion visit (simultaneous video + ActiMyo recording): Levodopa acute challenge and 2 hours of recording and medical monitoring
Other:
Controlled environment tests (series of tasks of everyday life)
Inclusion visit (simultaneous video + ActiMyo recording): Controlled environment tests (series of tasks of everyday life)
Standardized scales: MDS-UPDRS (Part II to IV) and RDRS
Inclusion visit (simultaneous video + ActiMyo recording): Standardized scales: MDS-UPDRS (Part II to IV) and RDRS
Device:
ActiMyo recording
Continuous activity recording with ActiMyo during the 2 weeks of study participation
Other:
Diary completion
Daily patient logbook completion during the 2 weeks of study participation

Locations

Country Name City State
France Service de Neurochirurgie, Hopital Henri Mondor Creteil
France Association Institut de Myologie Paris
France Département des Maladies du Système Nerveux, GH Pitie Salpatriere Paris

Sponsors (1)

Lead Sponsor Collaborator
Institut de Myologie, France

Country where clinical trial is conducted

France, 

Outcome

Type Measure Description Time frame Safety issue
Primary Tremors measurement by ActiMyo® PD patients only;
1 to 3 hours of simultaneous video + ActiMyo® sensors recording and physician evaluation (tasks of every day life, MDS-UPDRS, RDRS and physician worksheet); Small steps will be detected and quantified following ActiMyo® raw data analysis and results will be compared to physician evaluation.
Baseline
Primary Small steps measurement by ActiMyo® PD patients only;
1 to 3 hours of simultaneous video + ActiMyo® sensors recording and physician evaluation (tasks of every day life, MDS-UPDRS, RDRS and physician worksheet); Small steps will be detected and quantified following ActiMyo® raw data analysis and results will be compared to physician evaluation.
Baseline
Primary Dyskinesia measurement by ActiMyo® PD patients only;
1 to 3 hours of simultaneous video + ActiMyo® sensors recording and physician evaluation (tasks of every day life, MDS-UPDRS, RDRS and physician worksheet); Dyskinesia will be detected and quantified following ActiMyo® raw data analysis and results will be compared to physician evaluation.
Baseline
Secondary Continuous home activity measurement by ActiMyo® Subjects (PD patients and healthy volunteers) will wear ActiMyo® sensors everyday during 2 weeks and complete a hand-written paper diary to record their activity.
Activity variables will be deduced from ActiMyo® raw data analysis.
2 weeks
Secondary Off, On without dyskinesia, on with dyskinesia states measurement by ActiMyo® PD patients will wear ActiMyo® sensors everyday during 2 weeks and complete a hand-written paper diary to record their state (Off, On without dyskinesia, on with dyskinesia).
Off, On without dyskinesia, on with dyskinesia states will be measured following ActiMyo® raw data analysis and compared to hand-written paper diary indicating states.
2 weeks
Secondary Everyday life tasks measurement by ActiMyo® PD patients and healthy volunteers Every day life tasks will be measured following ActiMyo® raw data analysis. Baseline
See also
  Status Clinical Trial Phase
Completed NCT05029518 - 3-Way Crossover Study to Compare the PK (Pharmokinetics) and to Evaluate the Effect of Food on the Bioavailability Phase 1
Completed NCT05001152 - Taste Assessment of Ozanimod Phase 1
Completed NCT04493255 - A Study to Determine the Metabolism and Elimination of [14C]E7090 in Healthy Male Participants Phase 1
Completed NCT03457649 - IV Dose Study to Assess the Safety, Tolerability, PK, PD and Immunogenicity of ARGX-113 in Healthy Volunteers Phase 1
Completed NCT00995891 - Collection of Blood, Bone Marrow, and Buccal Mucosa Samples From Healthy Volunteers for Center for Human Immunology, Autoimmunity, and Inflammatory Diseases (CHI) Laboratory Research Studies
Completed NCT05050318 - Annual Study for Collection of Serum Samples in Children and Older Adults Receiving the 2021-2022 Formulations of Fluzone Quadrivalent Vaccine and Fluzone High-Dose Quadrivalent Vaccine, Respectively Phase 4
Completed NCT05043766 - Evaluation of Oral PF614 Relative to OxyContin Phase 1
Completed NCT04466748 - A Multiple Ascending Dose Pharmacology Study of Anaprazole in Healthy Chinese Subjects Phase 1
Completed NCT00746733 - Vyvanse and Adderall XR Given Alone and in Combination With Prilosec OTC Phase 1
Recruiting NCT05929651 - Study of Immunogenicity and Safety of MenQuadfi® as a Booster Vaccine in Toddlers 12 to 23 Months, Regardless of the Quadrivalent Meningococcal Conjugate Vaccine Used for Priming in Infancy Phase 4
Completed NCT05954039 - Evaluation of the Efficacy of a Dietary Supplement on Hair Loss and Hair Aspect N/A
Completed NCT05045716 - A Study of Subcutaneous Lecanemab in Healthy Participants Phase 1
Active, not recruiting NCT02747927 - Efficacy, Safety and Immunogenicity of Takeda's Tetravalent Dengue Vaccine (TDV) in Healthy Children Phase 3
Completed NCT05533801 - A Study to Demonstrate the Bioequivalence of Lecanemab Supplied in Vials and a Single-Use Auto-Injector (AI) in Healthy Participants Phase 1
Not yet recruiting NCT03931369 - Adaptation of Thirst to a Single Administration of Tolvaptan (TOLVATHIRST) Phase 2
Completed NCT03279146 - A Single Dose Study Evaluating PK of TXL Oral Formulations in Healthy Subjects Phase 1
Completed NCT06027437 - A Study to Assess the Relative Biological Availability and the Effect of Food on the Drug Levels of Danicamtiv in Healthy Adult Participants Phase 1
Recruiting NCT05619874 - Effects of Two Virtual HIFCT Programs in Adults With Abdominal Obesity N/A
Completed NCT05553418 - Investigational On-body Injector Clinical Study N/A
Completed NCT04092712 - Study Evaluating Pharmacokinetics and Mass Balance of [14C]-CTP-543 in Healthy Adult Male Volunteers Phase 1